Daylight Photodynamic Therapy for Actinic Keratoses

• Published in: American journal of clinical dermatology Vol. 19; no. 5; pp. 647 - 656
• Main Authors: Morton, Colin A., Braathen, Lasse R.
• Format: Journal Article
• Language: English
• Published: Cham Springer International Publishing 01.10.2018; Springer Nature B.V
• Subjects: Acids; Acne; Administration, Cutaneous; Aminolevulinic Acid - analogs & derivatives; Dermatologic Agents - therapeutic use; Dermatology; Drug Therapy, Combination - methods; Emulsions; FDA approval; Humans; Keratosis, Actinic - drug therapy; Medicine; Medicine & Public Health; Nanoemulsions; Nanoparticles - administration & dosage; Pain; Parasitic diseases; Pharmacology/Toxicology; Pharmacotherapy; Photochemotherapy - methods; Photodynamic therapy; Photosensitizing Agents - administration & dosage; Review Article; Skin - drug effects; Skin - radiation effects; Skin cancer; Skin diseases; Sunlight - adverse effects; Sunscreening Agents - administration & dosage; Treatment Outcome; Australia; United States > US; Europe; Latin America
• ISSN: 1175-0561; 1179-1888
• DOI: 10.1007/s40257-018-0360-y

Topical photodynamic therapy (PDT) using daylight is effective in the treatment of actinic keratoses (AKs), offering the potential for treatment of large fields such as full face and balding scalp, but with minimal therapy-associated pain. Comparison with conventional PDT indicates similar efficacy for thin and moderate-thickness AKs, but with significantly less discomfort/pain, driving a patient preference for daylight-mediated PDT (DL-PDT) compared with conventional PDT using high-intensity office/hospital-based light sources. Treatment protocol involves the application of a photosensitizing agent without occlusion and subsequent exposure to ambient daylight within 30 min, with patients exposed to daylight for 1.5–2.0 h. Pivotal randomized controlled trials in Europe and Australia have confirmed the efficacy of methyl aminolevulinic acid (MAL) DL-PDT in comparison with conventional MAL-PDT for mild and moderate-thickness lesions on the face and scalp. Initial clearance rates of 70–89% are reported. DL-PDT using a nanoemulsion aminolevulinic acid (ALA) has recently been shown to be at least as effective as MAL DL-PDT in treating mild and moderate-thickness AKs. DL-PDT may offer a better-tolerated method for treating patients with extensive AK disease. There is emerging literature on the potential for field PDT to reduce the number of new AKs developing, potentially preventing/slowing skin cancer development. Conventional PDT remains established as a therapy for Bowen’s disease (squamous cell carcinoma in situ), superficial and certain thin basal cell carcinomas (BCCs), and AKs. The evidence for the use of DL-PDT beyond AK is limited, although has been reported in actinic cheilitis, superficial BCC, and acne and cutaneous leishmaniasis. There is emerging interest in combination therapy for AK, using one or more field therapies such as DL-PDT as an option to complement with localized treatment for residual lesions. We review current recommendations and consider the appropriate place for DL-PDT in our treatment armamentarium.